X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.prnewswire.com/news-releases/pierre-fabre-laboratories-receive-positive-chmp-opinion-for-obgemsavibegron-in-overactive-bladder-syndrome-302128768.html
https://www.prnewswire.com/news-releases/sumitomo-pharma-announces-positive-topline-results-from-phase-3-clinical-studies-evaluating-vibegron-in-men-with-overactive-bladder-symptoms-receiving-pharmacological-therapy-for-benign-prostatic-hyperplasia-301923356.html
https://www.globenewswire.com/news-release/2020/12/23/2150263/0/en/Sumitovant-Biopharma-Announces-Urovant-Sciences-Receives-U-S-FDA-Approval-of-GEMTESA-vibegron-75-mg-Tablets-for-the-Treatment-of-Patients-with-Overactive-Bladder-OAB.html#:~:text=The%20Company's%20lead%20product%2C%20GEMTESA,incontinence%2C%20urgency%20and%20urinary%20frequency.
https://endpts.com/vivek-ramaswamys-vant-brainchildren-keep-bearing-fruit-with-urovants-fda-nod-for-incontinence-med-vibegron/
https://endpts.com/vivek-ramaswamys-vant-brainchildren-keep-bearing-fruit-with-urovants-fda-nod-for-incontinence-med-vibegron/
https://endpts.com/urovants-lead-drug-disappoints-in-mid-stage-study-as-first-big-fda-decision-looms/
https://www.businesswire.com/news/home/20201124005971/en/Urovant-Sciences-Announces-Topline-Data-from-Phase-2a-Study-of-Vibegron-for-the-Treatment-of-Irritable-Bowel-Syndrome-IBS-Pain-Did-Not-Meet-Primary-Endpoint
https://www.biopharmadive.com/news/sumitomo-acquire-urovant-deal-vibegron/589003/
https://www.fiercebiotech.com/biotech/as-urovant-preps-to-launch-myrbetriq-rival-it-s-all-systems-go-r-d
https://www.biospace.com/article/releases/urovant-sciences-announces-u-s-fda-acceptance-of-new-drug-application-for-vibegron-for-the-treatment-of-overactive-bladder/
https://www.in-pharmatechnologist.com/Article/2019/08/13/Urovant-ramps-up-spending-on-Codexis-ingredient-ahead-of-commercial-production
https://endpts.com/vivek-ramaswamys-urovant-claims-a-big-win-in-phiii-but-questions-linger-about-the-cheap-generic-comparator/
https://www.biospectrumasia.com/news/38/12766/codexis-signs-enzyme-supply-agreement-with-kyorin-pharma.html
https://www.contractpharma.com/contents/view_breaking-news/2019-02-06/codexis-kyorin-enter-supply-agreement/9778
https://www.businesswire.com/news/home/20181108005209/en/Urovant-Sciences-Completes-Patient-Enrollment-Phase-3
https://endpts.com/urovants-overactive-bladder-drug-scores-in-mid-stage-trial/
https://www.nasdaq.com/article/overactive-bladder-biotech-urovant-sciences-sets-terms-for-150-million-ipo-cm1023564
https://www.fiercebiotech.com/biotech/urovant-adds-gene-therapy-to-overactive-bladder-pipeline
Market Place
Share 
